Under-19 and Under-16 cricketers selected for KSCA Academy coaching

Mangaluru, June 20: A teenage boy lost his life after accidentally drowning in Netravati River at Boliyar village on the outskirts of the city yesterday.

The deceased has been identified as Mohammed Fazil (15), a resident of Nadupadavu village near Konaje. 

According to his family sources, Fazil had been to work in a horticultural land along with his friends on Saturday afternoon. 

On his way back he went to the river to wash his hands and legs. However, he lost his balance in the river and drowned, police sources said.

His body was retrieved at 2 p.m. A case was registered at jurisdictional Konaje police station.

Udupi, Jul 24: Udupi Power Corporation Limited (UPCL) has filed a complaint with the Cybercrime Police alleging that fake websites were created in the Corporation name and charging for registration to 1800 engineer jobs amidst covid-19 crisis. 

In a complaint submitted to Udupi Cyber Crime, Economic Offences & Narcotics (CEN) police station on Friday, UPCL Association General Manager K Shashidar alleged that four fake websites have been created in the name of UPCL and have claimed that 1,800 engineers posts are vacant in UPCL.

The fake websites have also been demanding Rs 500 fee for the registration of the job aspirants.

The FAKE websites are: www.udupipowerproject.com, www.upclindia.com, www.udupiproject.com, www.udupiproject.in. Helpline numbers +918046800985, +911149409800, +911149409807  too have been given in these fake websites.

Udupi CEN station has registered a case under Section 66(c), 66(d) of IT Act.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.